Personalis (PSNL) Expected to Announce Quarterly Earnings on Thursday

Personalis (NASDAQ:PSNLGet Free Report) is projected to announce its earnings results after the market closes on Thursday, February 27th. Analysts expect the company to announce earnings of ($0.32) per share and revenue of $15.48 million for the quarter. Investors that wish to register for the company’s conference call can do so using this link.

Personalis Price Performance

Shares of NASDAQ:PSNL opened at $4.57 on Tuesday. The company’s fifty day moving average price is $5.42 and its 200-day moving average price is $5.04. The firm has a market capitalization of $322.86 million, a price-to-earnings ratio of -2.72 and a beta of 1.73. Personalis has a one year low of $1.13 and a one year high of $7.20.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on PSNL shares. HC Wainwright lowered their price target on Personalis from $11.00 to $8.00 and set a “buy” rating on the stock in a research report on Monday, January 27th. Lake Street Capital upped their target price on Personalis from $7.00 to $9.00 and gave the stock a “buy” rating in a research note on Wednesday, January 8th. Finally, Needham & Company LLC reissued a “buy” rating and set a $7.25 price target on shares of Personalis in a research note on Wednesday, January 8th.

Check Out Our Latest Stock Analysis on PSNL

Personalis Company Profile

(Get Free Report)

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.

Featured Articles

Earnings History for Personalis (NASDAQ:PSNL)

Receive News & Ratings for Personalis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Personalis and related companies with MarketBeat.com's FREE daily email newsletter.